Your entry is only as good as your exit strategy...
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Gone now..
TEGY... only up 800%...lol
GESI...2 days in a row with well above average volume....what's up....
SUGO... .0016 X .0017 ...
AAVG...50/200 cross..need break of .0031..imo..
AAVG.. .0028 X .0029
ETRADE...
SUGO.. .0013 X .0014...dip before run over .002 imo..
Your welcome..
BLKL... .01 X .0115
Go for it....I will get it and it will sink and kill your move..
YUP..watching it but will shut it down...not a move for me now...maybe we can catch the next one..
BLKL... .095 X .01...extremely thin..
SUGO ...0018 up..
bragger...
SUGO... .0017 getting hit..
YUP..
nice to see some movement here...the past couple of days...
BLKL... .0085 X .009 ..Very thin..very very thin..
TEGY...2300% ...unreal..
.17 X .189....tightening up...
no shares...can't get filled...
TEGY...unreal....
MIMV....19 X .25...crazy thin...$1.50 target..
SIRG ... .0032 X .0035
Patience grasshopper....
NVLX...News...Nuvilex Points Toward Cell Encapsulation Technology Future to Expand Stem Cell Use for Late Stage Cancer Treatments
9:31 AM ET 3/8/12 | BusinessWire
Nuvilex, Inc. (OTCQB:NVLX), an emerging biotechnology provider of cell and gene therapy solutions, today discussed the potential use of the company's cell encapsulation technology with modified stem cells to treat late stage cancers.
Stem cell therapy is not new to physicians dealing with blood and bone cancers, with stem cell transplants being an important treatment for growing new bone marrow since the 1970s. Recent studies have indicated the potential for using stem cells across a much broader range of cancers is becoming a reality, mostly a result of advances in cell and molecular biology techniques.
Traditional chemotherapy works by targeting the fast-growing cells common to cancer tumors. Unfortunately, chemotherapeutics don't differentiate between healthy and cancerous cells. Patients suffering from metastatic cancers, where tumors have spread to multiple areas of the body, often have substantial difficulties with the chemotherapy needed to treat their disease.
In one case, researchers at City of Hope and St. Jude Children's Research Hospital may have found a way to treat cancers that have spread throughout the body more effectively. They used genetically modified stem cells to activate chemotherapeutic drugs at the tumor sites, so that normal tissue surrounding the tumor and throughout the body remain relatively unharmed. The stem cells were designed to produce a specific enzyme that converts the nontoxic prodrug into the chemotherapeutic agent. This method also targets the brain tumor treatment to remain localized within the brain, similar to the pancreatic cancer clinical trial carried out by SG Austria, providing for high dosage chemotherapy without affecting surrounding tissues and avoiding the severe side effects normally associated with cancer therapy.
Nuvilex believes that incorporating Cell-in-a-Box(R) encapsulation with this type of genetically modified stem cell, along with the proprietary cancer treatment being acquired, could significantly aid and improve patient outcomes.
Dr. Robert Ryan, Chief Executive Officer of Nuvilex, commented, "We are hopeful for the day when late stage cancers can be routinely and safely treated using genetically modified cells like those used in the pancreatic cancer trial, increasing the ability of clinicians to avoid inducing side effects that typically accompany aggressive chemotherapy and/or radiation. Our cell encapsulation technology will enable practitioners to target tumors while preserving the health of the surrounding tissues. We continue to look for leading stem cell and oncology researchers to partner with us as we bring this technology to market."
About Nuvilex
Nuvilex, Inc. (OTCQB:NVLX) is an emerging international biotechnology provider of clinically useful therapeutic live encapsulated cells and services for encapsulating live cells for the research and medical communities. Through our effort, all aspects of our corporate activities alone, and especially in concert with SG Austria, are rapidly moving toward completion, including closing our agreement. One of our planned offerings will include cancer treatments using the company's industry-leading live-cell encapsulation technology.
Safe Harbor Statement
The information provided may contain forward-looking statements and involve risks and uncertainties. Results, events and performances could vary from those contemplated. These statements involve risks and uncertainties which may cause actual results, expressed or implied, to differ from predicted outcomes. Risks and uncertainties include product demand, market competition, and Nuvilex's ability to meet current or future plans. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Nuvilex is not obliged to publicly release revisions to any forward-looking statement, to reflect events or circumstances afterward, or to disclose unanticipated occurrences, except as required under applicable laws.
SOURCE: Nuvilex, Inc.
Investor Relations Contact:
Marmel Communications, LLC
Marlin Molinaro
702-434-8692
mmolinarofc@aol.com
like it better at .005..
YUP..
I'm thinking it bounces right past .0045...
CATA..loading up here....we shall see...
WBSI.. .008 X .0084..alert @ .005 ...
SUGO... .0016 X .0017... .0017 getting slammed
love it...
O.T. Nothing like a little Rolling Stones in the morning....
CETH..News...Convergence Ethanol Completes Acquisition of Choco Placer Mine
9:02 AM ET 3/8/12 | Marketwire
Convergence Ethanol (PINKSHEETS: CETH) (the "Company") is pleased to announce it has acquired the gold-platinum Choco Placer mining operation (the "Project") near Union Panamericano, Colombia.
The Project consists of a contiguous land package covering 200 hectares with a purchase option agreement to acquire an additional 800 hectares of adjacent land. All required exploration, environmental and mining permits have been approved by national and regional authorities of Colombia. In addition, the Project has underlying support from surrounding citizens and communities.
The Choco Placer mine was in production as recently as August 2011 before operations were paused to pursue access to capital markets. Average weekly production at the mine was 21.8 troy ounces of gold and 7.3 ounces of platinum using standard alluvial separation techniques. The Company has verified that less than three percent of the land package has been worked. Previous operations included an on-site base camp for 20 laborers working two daily 10 hour shifts.
"Choco affords us the ability to implement our near-term business strategy to become a gold producer as quickly as possible," said President Joseph Arcaro. "Ultimately, it will allow us to fund our long-term growth plan to conduct exploration for lode prospects, where we will focus on identifying and proving up multi-million ounce gold resources."
Pursuant to the Agreement, the Company will issue 100,000,000 shares of restricted common stock to Mineros Alpha S.A.S. in exchange for the Project concessions. The Company also plans to change its name to Indemia Gold to more accurately reflect its new business operations.
About Indemia Gold Inc.
Indemia Gold is a results-driven precious metal mining company focused on monetizing the mineral wealth of Colombia. Its mission is to create shareholder value through near-term gold and platinum production at its flagship Choco Placer Mine and long-term development of district-scale hard rock projects with multi-million ounce resource potential. This two-pronged approach reduces risk for stakeholders through organic growth and minimal dilution while leaving upside potential intact. For more information on the Company, visit the corporate website at www.indemiagold.com.
Forward-Looking Statements
This news release may include "forward-looking statements" regarding Convergence Ethanol Inc. and its subsidiaries. Such forward-looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the United States Securities and Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor created by such sections. Where Convergence Ethanol Inc. expresses or implies an expectation or belief as to future events or results, such expectation or belief is believed to have a reasonable basis. However, forward-looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Convergence Ethanol Inc. does not undertake any obligation to update any forward-looking statement, except as required under applicable law.
Convergence Ethanol, Inc.
Joseph Arcaro
President
Tel: 1.310.291.5687
Email: info@indemiagold.com
SOURCE: Convergence Ethanol, Inc.
mailto:info@indemiagold.com
very nice..